Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Trial Profile

Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Lucanthone (Primary)
  • Indications Brain metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018 as per ClinicalTrials.gov record.
    • 10 Aug 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
    • 24 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top